Cardio3 BioSci raises 1.37M euros
Cardio3 BioSciences, a Belgian biotechnology company specializing in cell-based therapies for the treatment of cardiovascular diseases, has raised 7.2 million euros ($9.6 million) in a series B fund raising round.
The new funds, which have come from a range of new and existing investors, will be used to finance the clinical development of the company's lead product, C-Cure, a unique therapy that allows the differentiation of a patient's own cells into "cardiopoietic" ones that grow into new heart cells and repair heart muscle. The firm says this product holds the promise for a treatment that could fundamentally change the future of heart failure patients, one of the world's largest medical needs.
Cardio3 plans to enroll shortly around 240 patients in a clinical trial with C-Cure to evaluate its potential in the treatment of heart failure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze